Management of metastatic cervical cancer: review of the literature.

Autor: Long HJ 3rd

Publikováno v: Journal of Clinical Oncology; 7/10/2007, Vol. 25 Issue 20, p2966-2974, 9p

Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).

Autor: Penson RT; Division of Hematology and Oncology, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Electronic address: rpenson@partners.org., Huang HQ; NRG Oncology/Gynecologic Oncology Group, Roswell Park Cancer Institute, Buffalo, NY, USA., Wenzel LB; University of California, Irvine Medical Center, Orange, CA, USA., Monk BJ; University of Arizona Cancer Center and Creighton University at St Joseph's Hospital and Medical Center, Phoenix, AZ, USA., Stockman S; University of Iowa Hospitals, Iowa City, IA, USA., Long HJ 3rd; Mayo Clinic, Rochester, MN, USA., Ramondetta LM; MD Anderson Cancer Center, Houston, TX, USA., Landrum LM; Oklahoma University Health Science Center, Oklahoma City, OK, USA., Oaknin A; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain., Reid TJ; University of Cincinnati College of Medicine/Women's Cancer Center at Kettering, Kettering, OH, USA., Leitao MM; Memorial Sloan-Kettering Cancer Center, New York, NY, USA., Method M; Michiana Hematology Oncology PC-Mishawaka, Mishawaka, IN, USA., Michael H; Indiana University School of Medicine, Indianapolis, IN, USA., Tewari KS; University of California, Irvine Medical Center, Orange, CA, USA.

Publikováno v: The Lancet. Oncology [Lancet Oncol] 2015 Mar; Vol. 16 (3), pp. 301-11. Date of Electronic Publication: 2015 Jan 29.

Improved survival with bevacizumab in advanced cervical cancer.

Autor: Tewari KS; From the University of California, Irvine, Medical Center, Orange (K.S.T.); Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo (M.W.S., H.H.); Mayo Clinic, Rochester, MN (H.J.L.); Massachusetts General Hospital, Boston (R.T.P.); M.D. Anderson Cancer Center, Houston (L.M.R.); University of Oklahoma, Oklahoma City (L.M.L.); Vall d'Hebron University Hospital, Barcelona (A.O.); University of Cincinnati College of Medicine-Women's Cancer Center at Kettering, Kettering, OH (T.J.R.); Memorial Sloan-Kettering Cancer Center, New York (M.M.L.); Indiana University School of Medicine, Indianapolis (H.E.M.); and the University of Arizona Cancer Center and Creighton University at St. Joseph's Hospital and Medical Center, Phoenix (B.J.M.)., Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ

Publikováno v: The New England journal of medicine [N Engl J Med] 2014 Feb 20; Vol. 370 (8), pp. 734-43.

Prevention, diagnosis, and treatment of cervical cancer.

Autor: Long HJ 3rd; Division of Medical Oncology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. long.harry@mayo.edu, Laack NN, Gostout BS

Publikováno v: Mayo Clinic proceedings [Mayo Clin Proc] 2007 Dec; Vol. 82 (12), pp. 1566-74.

Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study.

Autor: Long HJ 3rd; Mayo Clinic, Department of Medical Oncology, East 12B Mayo Building, 200 First Street, Southwest, Rochester, MN 55905-0001, USA. long.harry@mayo.edu, Monk BJ, Huang HQ, Grendys EC Jr, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV

Publikováno v: Gynecologic oncology [Gynecol Oncol] 2006 Mar; Vol. 100 (3), pp. 537-43. Date of Electronic Publication: 2005 Oct 10.